2024-03-14 14:00:00
The operation is very large-scale for a French biotech. Founded just 5 years ago, the company Amolyt Pharma announced on March 14, 2024 its upcoming acquisition by AstraZeneca for a potential amount of 1.05 billion dollars (approximately 960 million euros). Specializing in therapeutic peptides targeting rare endocrine and metabolic diseases, Amolyt should be integrated into AstraZeneca’s rare diseases division. In this case, this is the entity Alexion, an American laboratory acquired in 2021 for around 35 billion euros by the Anglo-Swedish pharmaceutical giant. Scheduled to be finalized in the third quarter of 2024, the acquisition of Amolyt comes in two stages: first an initial amount of $800 million (731 million euros), then a subsequent potential payment of $250 million (around 228 million euros) depending on the success of certain development stages.
Amolyt Pharma’s flagship molecule originating from American research
[…]
This article is reserved for our L’Usine Nouvelle subscribers
Support expert journalism.
Already subscribed? Log in
I will tell you
source
Selected for you
1710455083
#forefront #endocrine #diseases #Lyon #biotech #Amolyt #bought #AstraZeneca #million #euros
